- Q3 2026 revenue increased 15.6% YoY to $410.1M, driven by an 18.1% gain in Thrombectomy revenue ($279.2M).
- Net income dropped to $42.3M from $45.9M in Q3 2025; diluted EPS fell to $1.07 compared to $1.17 in the prior-year period.
- 9-month net income decreased to $109.7M from $130.3M, highlighting ongoing operating margin pressure despite top-line growth.
?? Negative AI Sentiment (-2.5 / 10)